This is a virtual, patient-centric, observational study that will follow approximately 60 participants through 8 weeks following initiation of Remodulin therapy via their UTC-developed next generation infusion pump and consists of remote and electronic assessments administered to patient via the uMotif® data capture platform at Study Enrollment, Day 1 (or Combined Study Enrollment/Day 1, if applicable), Week 2, Week 4, and Week 8 or Early Withdrawal (if applicable).~The study population will consist of 2 cohorts of PAH patients:~De Novo Cohort: patients new to parenteral prostacyclin-class therapy.~Transition Cohort: patients who are currently receiving SC treprostinil therapy via a previous generation infusion pump.~The De Novo Cohort will initiate subcutaneous (SC) Remodulin via a next generation infusion pump as prescribed by their healthcare professional. Participants will be followed from time of enrollment through 8 weeks following Day 1 (ie, start of infusion of Remodulin via a next generation infusion pump) or until discontinuation of Remodulin (early withdrawal), whichever comes first.~The Transition Cohort will continue to receive SC treprostinil as prescribed by their healthcare professional via their current (ie, previous generation) infusion pump until transitioning to delivery of Remodulin via a next generation infusion pump. Participants will be followed from time of enrollment through 8 weeks following Day 1 (ie, first day patient transitions to delivery of Remodulin via a next generation infusion pump) or until discontinuation of Remodulin (early withdrawal), whichever comes first.~Following the completion of study assessments at Week 8 or Early Withdrawal (if applicable), participants will continue Remodulin therapy via their infusion pump at their prescriber's discretion.
To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related to use of United Therapeutics Corporation (UTC)-developed next-generation infusion pumps to administer Remodulin in patients with Pulmonary Arterial Hypertension (PAH).